PHAT Phathom Pharmaceuticals
- 6.960
- 0.0000.00%
- 7.200
- +0.240+3.45%
Phathom Pharmaceuticals News
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Nabulsi Azmi
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Henderson Molly
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director KARBE FRANK
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Parikh Asit
Phathom Pharmaceuticals | 8-K: Current report
Phathom Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.2%)
Phathom Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Phathom Pharmaceuticals | 8-K: Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Phathom Pharmaceuticals | SCHEDULE 13G/A: Others
Phathom Pharmaceuticals | SCHEDULE 13G: Others
Phathom Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Jennison Associates LLC(10.4%)
Phathom Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.2%)
Phathom Pharmaceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-James N. Topper(18.0%),Patrick J. Heron(18.0%), etc.
Phathom Pharmaceuticals | 8-K: Current report
Phathom Pharmaceuticals | 424B5: Prospectus
Phathom Pharmaceuticals | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses
Phathom Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Phathom Pharmaceuticals | 8-K: Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Phathom Pharmaceuticals | 8-K: Current report
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Nabulsi Azmi
No Data